Can I Take Vitamin B6 With Wegovy? A Women's Health Guide

The Short Answer: Can You Take Vitamin B6 With Wegovy?

Yes, you can take vitamin B6 with Wegovy at standard dietary supplement doses, and there is no documented pharmacokinetic interaction between semaglutide and pyridoxine. The two substances work through entirely different biological pathways and do not appear to affect each other's absorption, metabolism, or elimination in any clinically meaningful way.

The caution worth knowing is dose-dependent and applies to B6 on its own: chronic intake above 200 mg/day has been linked to sensory peripheral neuropathy in case reports and observational data, even without any GLP-1 medication involved. Wegovy does not appear to make this risk worse, but that ceiling matters when you are choosing a supplement dose.

Your life stage, your reason for taking B6, and whether you have PCOS, are perimenopausal, or might become pregnant all shape the practical advice significantly. Each scenario is addressed below.

How Wegovy Works and Why Supplement Interactions Happen

Semaglutide's mechanism in brief

Wegovy is a GLP-1 receptor agonist approved by the FDA in June 2021 for chronic weight management in adults with a body mass index (BMI) of 30 or higher, or BMI of 27 or higher with at least one weight-related condition. It binds GLP-1 receptors in the hypothalamus, gut, and pancreas, slowing gastric emptying, reducing appetite, and enhancing glucose-dependent insulin secretion.

The STEP 1 trial showed a mean weight reduction of 14.9% over 68 weeks with semaglutide 2.4 mg weekly versus 2.4% with placebo. Women made up 74.1% of the STEP 1 population, which is genuinely encouraging for sex-specific data, though subgroup analyses by hormonal status (menopausal vs premenopausal) were not primary endpoints and remain an acknowledged evidence gap.

Why GLP-1s change supplement absorption

Semaglutide slows gastric emptying. This matters for any oral supplement because slower transit time can alter the time-to-peak concentration of certain vitamins and minerals. For fat-soluble vitamins (A, D, E, K), delayed gastric emptying may theoretically affect absorption timing. Vitamin B6 is water-soluble and absorbed primarily in the jejunum by a saturable, carrier-mediated mechanism. The clinical significance of slowed gastric emptying on B6 absorption has not been directly studied in women taking semaglutide. That is an honest evidence gap: what exists is mechanistic reasoning, not a dedicated pharmacokinetic trial.

What Is Vitamin B6 and Why Do Women Take It?

Biochemical roles relevant to women

Pyridoxine (vitamin B6) is a water-soluble coenzyme involved in over 100 enzymatic reactions, including amino acid metabolism, neurotransmitter synthesis (serotonin, dopamine, GABA), and one-carbon metabolism. The recommended dietary allowance (RDA) for adult women is 1.3 mg/day, rising to 1.5 mg/day after age 50, according to the National Institutes of Health Office of Dietary Supplements.

Common reasons women take supplemental B6

Women reach for B6 supplements for several distinct reasons across life stages:

• Premenstrual syndrome (PMS) and PMDD. A Cochrane review found some evidence that B6 up to 100 mg/day may relieve PMS symptoms, though the trial quality was rated low. Doses used in these studies ranged from 50 to 100 mg/day.
• Nausea of pregnancy. The ACOG Practice Bulletin on nausea and vomiting in pregnancy recommends B6 (pyridoxine) 10 to 25 mg three times daily as first-line pharmacologic treatment.
• PCOS. Women with PCOS often have elevated homocysteine due to insulin resistance. B6 is a cofactor in homocysteine metabolism, and some providers recommend it alongside folate and B12 in this population.
• Perimenopause and mood support. B6 supports serotonin and dopamine synthesis. Some perimenopausal women use it for mood and sleep, though clinical evidence for this specific application is limited.
• Multivitamins. Many standard multivitamins contain 2 to 10 mg of B6, well below any threshold of concern.

The Interaction Question: Pharmacokinetic vs Pharmacodynamic

No pharmacokinetic interaction identified

A pharmacokinetic interaction means one substance changes how the other is absorbed, distributed, metabolized, or excreted. No published pharmacokinetic study has identified a direct interaction between semaglutide and pyridoxine. Semaglutide is metabolized by proteolytic cleavage and does not use cytochrome P450 enzymes, meaning the extensive drug-drug interaction pathways that affect most small-molecule drugs simply do not apply here.

B6 itself is not a meaningful CYP enzyme inducer or inhibitor at supplemental doses, so it does not alter semaglutide's plasma half-life of approximately one week.

Pharmacodynamic considerations: where the real nuance lives

A pharmacodynamic interaction occurs when two agents affect the same physiological outcome, either reinforcing or opposing each other. Here, the relevant concern is nausea.

Wegovy causes nausea in approximately 44% of patients during dose escalation. B6 has antiemetic properties and is used clinically for pregnancy-related nausea. Some clinicians informally suggest B6 might blunt Wegovy-associated nausea, and this is plausible on mechanistic grounds (B6 influences serotonin pathways involved in the emetic reflex). No randomized controlled trial has tested this combination specifically in the Wegovy context.

The WomanRx Dose-Risk Framework for B6 alongside Wegovy:

| B6 Daily Dose | Risk Level | Practical Note | |---|---|---| | Food sources only (avg 1-2 mg) | Negligible | No concern with Wegovy | | Standard multivitamin (2-10 mg) | Negligible | No concern | | Low-dose supplement (25-50 mg) | Low | Reasonable for PMS, PCOS homocysteine support | | Mid-range (50-100 mg) | Low to moderate | At the tolerable upper limit; PMS trial doses | | High-dose (>100 mg) | Moderate to high | Neuropathy risk exists without Wegovy; avoid unless prescribed | | Very high-dose (>200 mg) | High | Sensory neuropathy documented; do not use |

High-Dose B6 and Peripheral Neuropathy: What You Need to Know

Peripheral neuropathy from excess B6 is real and does not require decades of use to develop. A 2023 analysis published in the New England Journal of Medicine described cases of sensory neuropathy linked to B6 supplements at doses between 50 and 1,000 mg/day, with some cases occurring in women who had been supplementing for fewer than six months. Symptoms include numbness, tingling, and burning sensations in the hands and feet, starting distally and moving proximally.

The European Food Safety Authority set a tolerable upper intake level of 25 mg/day for long-term use, lower than the U.S. Institute of Medicine's 100 mg/day, reflecting ongoing uncertainty about the threshold. The discrepancy between these two bodies is itself an evidence gap worth naming.

Does Wegovy worsen neuropathy risk from B6? There is no data suggesting it does. Semaglutide does not have a neuropathy signal in its own right; the SUSTAIN and STEP trial programs did not identify peripheral neuropathy as a Wegovy-specific adverse event. The neuropathy risk is B6-dose-driven, not semaglutide-driven.

Life-Stage Guide: How This Changes Across Your Reproductive Years

Reproductive years (menstruating, not trying to conceive)

If you are in your reproductive years, using Wegovy for weight management, and taking B6 for PMS or cycle-related mood symptoms, doses up to 50 to 100 mg/day appear reasonable based on the existing PMS literature. Time your B6 with food. Take it at least 30 minutes before your Wegovy injection day is not necessary from an interaction standpoint, but taking it consistently with a meal supports absorption.

One practical note: Wegovy can reduce food intake substantially during dose escalation. If your dietary B6 drops because you are eating less overall, a low-dose supplement of 2 to 10 mg (as in a standard multivitamin) makes sense nutritionally.

Trying to conceive (TTC)

Stop Wegovy before trying to conceive. ACOG and the manufacturer recommend discontinuing semaglutide at least two months before attempting pregnancy, as the drug's one-week half-life means residual exposure could persist into early embryonic development. Animal studies showed embryofetal toxicity at clinically relevant exposures.

During the TTC window, B6 remains appropriate. Starting a prenatal vitamin that includes 2 to 10 mg of B6 is sensible. Your provider may suggest low-dose standalone B6 (10 to 25 mg) if you have a history of first-trimester nausea from a prior pregnancy.

Pregnancy

Wegovy is contraindicated in pregnancy. Full stop. If you become pregnant while on Wegovy, contact your prescriber immediately to discontinue the medication.

B6 in pregnancy is a different story entirely. ACOG recommends pyridoxine 10 to 25 mg three times daily as the first-line pharmacologic treatment for nausea and vomiting of pregnancy, often combined with doxylamine. The FDA pregnancy category for B6 at therapeutic doses is Category A, meaning adequate and well-controlled studies have not shown a risk to the fetus. Prenatal vitamins universally contain B6.

The clinical scenario where both are discussed is the transition: a woman stops Wegovy, waits the recommended two-month washout, conceives, and then uses B6 for nausea. These are sequential uses, not concurrent ones.

Postpartum and lactation

Wegovy is not recommended during breastfeeding due to insufficient human data on transfer into breast milk. The FDA prescribing information advises against use during lactation.

B6 does transfer into breast milk. The NIH Office of Dietary Supplements notes that the B6 content of breast milk reflects maternal intake, and lactating women have an RDA of 2.0 mg/day. Supplementing at multivitamin doses (2 to 10 mg) is considered safe during breastfeeding. High-dose B6 above 100 mg/day is not recommended in lactating women, not because of an interaction with Wegovy (which should not be used during lactation) but because of neonatal exposure concerns.

Perimenopause

Perimenopause is one of the most common life stages in which women are prescribed Wegovy, given the metabolic changes that accelerate weight gain in the menopause transition. Estrogen decline affects serotonin metabolism, which is partly B6-dependent. Women in perimenopause sometimes take B6 for mood, sleep quality, or to support a methylated B-complex for cardiovascular homocysteine management.

No perimenopause-specific interaction data exist for B6 plus semaglutide. At doses up to 50 mg/day, the combination appears safe. Women in perimenopause on hormone therapy should note that estrogen may increase the metabolic demand for B6, a finding from older oral contraceptive studies that may apply to higher estrogen HRT doses, though direct evidence in the HRT context is limited.

Postmenopause

The RDA for B6 rises to 1.5 mg/day after age 50. Postmenopausal women on Wegovy for metabolic weight management are not at any additional risk from standard B6 supplementation. The neuropathy ceiling of 100 mg/day (or the more conservative 25 mg/day threshold used by European regulators) still applies.

PCOS and Wegovy: Does B6 Add Anything?

Women with PCOS are frequently prescribed semaglutide off-label or, increasingly, on-label as Wegovy for the weight-related aspects of their condition. A 2022 meta-analysis in Fertility and Sterility found that GLP-1 receptor agonists reduced body weight, fasting insulin, and testosterone in women with PCOS, with effect sizes meaningful for symptom management.

B6 in PCOS has been studied primarily in the context of homocysteine reduction and PMS-like symptoms, which are more common in PCOS. There is no RCT combining B6 with GLP-1 therapy in PCOS. What is known: B6 as a cofactor for cystathionine beta-synthase helps metabolize homocysteine, which runs elevated in insulin-resistant states. Given that Wegovy also improves insulin sensitivity, the two may work complementarily on cardiovascular risk markers, though this is mechanistic reasoning, not direct trial evidence.

Nausea is a genuine concern in PCOS plus Wegovy. Women with PCOS may experience stronger nausea during Wegovy dose escalation due to gut motility differences and dietary patterns. B6 at 25 mg taken 30 to 60 minutes before eating may offer modest antiemetic benefit during the first eight to twelve weeks of dose escalation, though no PCOS-specific trial has tested this protocol.

Practical Dosing and Timing Guidance

What dose of B6 is reasonable with Wegovy?

• For general nutritional insurance during caloric restriction: use a comprehensive multivitamin containing 2 to 10 mg of B6.
• For PMS or cycle-related mood support: 50 to 100 mg/day is the dose range used in published trials, but stay at the lower end (50 mg) for long-term use.
• For Wegovy-associated nausea (off-label): 10 to 25 mg before meals has the most parallel data from pregnancy nausea research.
• Avoid standalone B6 supplements above 100 mg/day without explicit prescriber guidance.

Timing with Wegovy injection

Wegovy is injected subcutaneously once weekly. B6 is an oral supplement taken daily. There is no pharmacokinetic reason to separate their timing. Take B6 with your largest meal of the day to maximize absorption and minimize any stomach discomfort.

Signs to watch for

Watch for tingling or numbness in your fingers or toes if you are taking B6 above 50 mg/day. This is the earliest sign of sensory neuropathy and warrants stopping the supplement and telling your prescriber. Neuropathy from B6 is generally reversible when caught early, though recovery can take months.

Who This Approach Is Right For (and Who It Is Not)

Good candidates for B6 alongside Wegovy

• Women in reproductive years using B6 for PMS at 50 to 100 mg/day
• Women with PCOS using B6 as part of a homocysteine-lowering B-complex at standard doses
• Perimenopausal women taking a methylated B-complex at multivitamin doses
• Anyone using Wegovy who eats significantly less and wants nutritional insurance via a standard multivitamin with B6

Who should use caution or avoid B6 at higher doses

• Women already experiencing any peripheral tingling on Wegovy (unlikely to be B6-caused unless they are supplementing, but worth ruling out)
• Women taking isoniazid for tuberculosis prophylaxis alongside Wegovy: isoniazid is a B6 antagonist and may require supplemental B6, but that clinical situation warrants a pharmacist review of all three agents together
• Women on high-dose B-complex formulations from multiple supplement sources simultaneously (stacking risk is real if a multivitamin, a B-complex, and a standalone B6 are all taken together)
• Women who are pregnant or planning pregnancy imminently (Wegovy should be stopped, changing the entire equation)

Pregnancy and Lactation: Required Safety Summary

Wegovy in pregnancy: contraindicated. Animal reproductive toxicology studies showed embryofetal toxicity at exposures below the clinical dose. The FDA prescribing information states that Wegovy should be discontinued at least two months before a planned pregnancy. There is no human pregnancy safety registry with sufficient numbers to draw reassuring conclusions. If you become pregnant while taking Wegovy, discontinue immediately and contact your prescriber.

Contraception requirement: Women of reproductive potential taking Wegovy should use reliable contraception unless they are actively trying to conceive. Wegovy does not appear to reduce oral contraceptive efficacy directly, but the two-month washout before conception means unintended pregnancy while on the drug is the scenario to prevent.

B6 in pregnancy: Category A, first-line antiemetic. ACOG's Practice Bulletin lists B6 (pyridoxine) 10 to 25 mg up to three times daily as the initial recommended treatment for nausea and vomiting of pregnancy. The combination product doxylamine/pyridoxine (Diclegis/Bonjesta) carries FDA Category A classification.

B6 in lactation: Transfers into breast milk; multivitamin doses (2 to 10 mg/day) are safe. High doses above 100 mg/day are not recommended in lactating women. Wegovy should not be used during lactation.

A Note on the Evidence Gap for Women

Women have historically been under-represented in drug trials, and the GLP-1 supplement interaction literature is no exception. The STEP trial program enrolled a majority of women, which is genuinely better than most cardiovascular trials, but subgroup analyses by menopausal status, contraceptive use, or hormonal status were not primary or pre-specified secondary endpoints. No dedicated pharmacokinetic study of semaglutide in postmenopausal compared to premenopausal women has been published. The B6 neuropathy literature is similarly mixed, with most high-dose neuropathy cases reported in women, though whether this reflects higher rates of supplementation in women or genuine sex-specific susceptibility is not established.

When your provider or pharmacist says "there's no known interaction between B6 and Wegovy," that is accurate and based on mechanism and absence of case reports, not on a dedicated interaction trial. The distinction matters for shared decision-making.